Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020

被引：15

作者：

Elkrief, A. ^{[1
,2
,3
]}

Joubert, P. ^{[4
]}

Florescu, M. ^{[3
,5
]}

Tehfe, M. ^{[3
,5
]}

Blais, N. ^{[3
,5
]}

Routy, B. ^{[3
,5
]}

机构：

[1] Sir Mortimer B Davis Jewish Hosp, Segal Canc Ctr, Montreal, PQ, Canada

[2] McGill Univ, Hlth Ctr, Cedars Canc Ctr, Montreal, PQ, Canada

[3] Ctr Hosp Univ Montreal, Ctr Rech, Montreal, PQ, Canada

[4] Ist Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada

[5] Ctr Hosp Univ Montreal, Div Hematol Oncol, Montreal, PQ, Canada

来源：

CURRENT ONCOLOGY | 2020年 / 27卷 / 01期

关键词：

Lung cancer; immunotherapy; targeted therapy; chemotherapy; biomarkers; PREVIOUSLY TREATED PATIENTS; PHASE-III; ELDERLY-PATIENTS; OPEN-LABEL; CHEMOTHERAPY; EGFR; STAGE; IMMUNOTHERAPY; OSIMERTINIB; CRIZOTINIB;

D O I：

10.3747/co.27.5953

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancer is the most commonly diagnosed cancer in Canada and remains associated with high mortality. Nevertheless, recent advances in the fields of immuno-oncology and precision medicine have led to significant improvements in clinical outcome in metastatic non-small-cell lung cancer (NSCLC). Those improvements were facilitated by a greater understanding of the biologic classification of NSCLC, which catalyzed discoveries of novel therapies. Here, we present a comprehensive review of the recent avalanche of practice-changing trials in metastatic NSCLC, and we offer an approach to the management of this disease from a Canadian perspective. We begin with an overview of the pathologic and molecular characterization of metastatic NSCLC. Next, we review the indications for currently approved immune checkpoint inhibitors, and we provide an approach to the management of disease with a driver mutation. Finally, we address future avenues in both diagnostics and therapeutics for patients with advanced and metastatic NSCLC.

引用

页码：52 / 60

页数：9

共 60 条

[1]

[Anonymous], J GERIATR ONCOL

[2]

[Anonymous], 2019, JAMA ONCOL

[3] Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis [J].

Antonia, Scott J. ;

Borghaei, Hossein ;

Ramalingam, Suresh S. ;

Horn, Leora ;

De Castro Carpeno, Javier ;

Pluzanski, Adam ;

Burgio, Marco A. ;

Garassino, Marina ;

Chow, Laura Q. M. ;

Gettinger, Scott ;

Crino, Lucio ;

Planchard, David ;

Butts, Charles ;

Drilon, Alexander ;

Wojcik-Tomaszewska, Joanna ;

Otterson, Gregory A. ;

Agrawal, Shruti ;

Li, Ang ;

Penrod, John R. ;

Brahmer, Julie .

LANCET ONCOLOGY, 2019, 20 (10) :1395-1408

[4] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer [J].

Arbour, Kathryn C. ;

Mezquita, Laura ;

Long, Niamh ;

Rizvi, Hira ;

Auclin, Edouard ;

Ni, Andy ;

Martinez-Bernal, Gala ;

Ferrara, Roberto ;

Lai, W. Victoria ;

Hendriks, Lizza E. L. ;

Sabari, Joshua K. ;

Caramella, Caroline ;

Plodkowski, Andrew J. ;

Halpenny, Darragh ;

Chaft, Jamie E. ;

Planchard, David ;

Riely, Gregory J. ;

Besse, Benjamin ;

Hellmann, Matthew D. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) :2872-+

[5] Novel patterns of response under immunotherapy [J].

Borcoman, E. ;

Kanjanapan, Y. ;

Champiat, S. ;

Kato, S. ;

Servois, V. ;

Kurzrock, R. ;

Goel, S. ;

Bedard, P. ;

Le Tourneau, C. .

ANNALS OF ONCOLOGY, 2019, 30 (03) :385-396

[6] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[7] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer [J].

Camidge, D. R. ;

Kim, H. R. ;

Ahn, M. -J. ;

Yang, J. C. -H. ;

Han, J. -Y. ;

Lee, J. -S. ;

Hochmair, M. J. ;

Li, J. Y. -C. ;

Chang, G. -C. ;

Lee, K. H. ;

Gridelli, C. ;

Delmonte, A. ;

Garcia Campelo, R. ;

Kim, D. -W. ;

Bearz, A. ;

Griesinger, F. ;

Morabito, A. ;

Felip, E. ;

Califano, R. ;

Ghosh, S. ;

Spira, A. ;

Gettinger, S. N. ;

Tiseo, M. ;

Gupta, N. ;

Haney, J. ;

Kerstein, D. ;

Popat, S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2027-2039

[8]

Canadian Cancer Statistics Advisory Committee, 2019, CAN CANC STAT 2019

[9] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].

Carbone, D. P. ;

Reck, M. ;

Paz-Ares, L. ;

Creelan, B. ;

Horn, L. ;

Steins, M. ;

Felip, E. ;

van den Heuvel, M. M. ;

Ciuleanu, T. -E. ;

Badin, F. ;

Ready, N. ;

Hiltermann, T. J. N. ;

Nair, S. ;

Juergens, R. ;

Peters, S. ;

Minenza, E. ;

Wrangle, J. M. ;

Rodriguez-Abreu, D. ;

Borghaei, H. ;

Blumenschein, G. R. ;

Villaruz, L. C. ;

Havel, L. ;

Krejci, J. ;

Corral Jaime, J. ;

Chang, H. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Chen, A. C. ;

Socinski, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426

[10] Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 [J].

Champiat, Stephane ;

Dercle, Laurent ;

Ammari, Samy ;

Massard, Christophe ;

Hollebecque, Antoine ;

Postel-Vinay, Sophie ;

Chaput, Nathalie ;

Eggermont, Alexander ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Ferte, Charles .

CLINICAL CANCER RESEARCH, 2017, 23 (08) :1920-1928

← 1 2 3 4 5 6 →